Pharsight

Drugs that contain Sumatriptan Succinate

1. Alsuma patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7811254 MERIDIAN MEDCL Autoinjector with needle depth adapter
Aug, 2027

(3 years from now)

Market Authorisation Date: 29 June, 2010

Treatment: Acute treatment of migraine attacks, with or without aura, and the treatment of cluster headache episodes

Dosage: INJECTABLE;SUBCUTANEOUS

More Information on Dosage

ALSUMA family patents

Family Patents

2. Onzetra Xsail patents expiration

ONZETRA XSAIL's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8047202 CURRAX Nasal devices
Jul, 2023

(7 months ago)

US8327844 CURRAX Nasal delivery method
Oct, 2023

(4 months ago)

US9119932 CURRAX Nasal delivery device
Apr, 2024

(a month from now)

US7975690 CURRAX Nasal devices
Aug, 2025

(1 year, 5 months from now)

US9108015 CURRAX Nasal delivery devices
Sep, 2025

(1 year, 6 months from now)

US8590530 CURRAX Nasal delivery devices
Sep, 2025

(1 year, 6 months from now)

US11571531 CURRAX Powder delivery devices
Feb, 2026

(1 year, 11 months from now)

US10124132 CURRAX Nasal delivery
Mar, 2027

(3 years from now)

US10398859 CURRAX Nasal delivery devices
Dec, 2027

(3 years from now)

US8875704 CURRAX Nasal administration
Apr, 2028

(4 years from now)

US10722667 CURRAX Nasal administration
Dec, 2028

(4 years from now)

US10076615 CURRAX Nasal delivery
Jul, 2029

(5 years from now)

US8550073 CURRAX Nasal delivery
Oct, 2029

(5 years from now)

US8899229 CURRAX Powder delivery devices
Aug, 2030

(6 years from now)

US9649456 CURRAX Nasal administration
Oct, 2030

(6 years from now)

US8978647 CURRAX Nasal delivery
Dec, 2030

(6 years from now)

US10478574 CURRAX Nasal administration
Nov, 2033

(9 years from now)

US10076614 CURRAX Nasal delivery devices
Oct, 2034

(10 years from now)

Market Authorisation Date: 27 January, 2016

Treatment: Method of drug delivery via the nasal cavity; Acute treatment of migraine by delivering a powdered substance comprising sumatriptan via a breath-powered delivery device; Acute treatment of migraine; T...

Dosage: POWDER;NASAL

More Information on Dosage

ONZETRA XSAIL family patents

Family Patents

3. Sumavel Dosepro patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8343130 ENDO VENTURES LTD Needleless injector
Oct, 2022

(1 year, 4 months ago)

US8241244 ENDO VENTURES LTD Needleless injector drug capsule and a method for filling thereof
Nov, 2022

(1 year, 3 months ago)

US8491524 ENDO VENTURES LTD Needleless injector drug capsule and a method for filling thereof
Nov, 2022

(1 year, 3 months ago)

US8267903 ENDO VENTURES LTD Casing
Mar, 2023

(11 months ago)

US8118771 ENDO VENTURES LTD Needleless injector drug capsule and a method for filling thereof
Aug, 2023

(6 months ago)

US8241243 ENDO VENTURES LTD Needleless injector drug capsule and a method for filling thereof
Aug, 2023

(6 months ago)

US8287489 ENDO VENTURES LTD Device for readying a needle free injector for delivery
Dec, 2024

(9 months from now)

US7901385 ENDO VENTURES LTD Casing
Jul, 2026

(2 years from now)

US7776007 ENDO VENTURES LTD Device for readying a needle free injector for delivery
Nov, 2026

(2 years from now)

Market Authorisation Date: 15 July, 2009

Treatment: NA

Dosage: INJECTABLE;SUBCUTANEOUS

More Information on Dosage

SUMAVEL DOSEPRO family patents

Family Patents

4. Zecuity patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6745071 TEVA BRANDED PHARM Iontophoretic drug delivery system
Feb, 2023

(1 year, 9 days ago)

US7973058 TEVA BRANDED PHARM Transdermal methods and systems for the delivery of anti-migraine compounds
Apr, 2027

(3 years from now)

US8597272 TEVA BRANDED PHARM Pharmacokinetics of iontophoretic sumatriptan administration
Apr, 2027

(3 years from now)

US9427578 TEVA BRANDED PHARM Pharmacokinetics of iontophoretic sumatriptan administration
Apr, 2027

(3 years from now)

US8470853 TEVA BRANDED PHARM Transdermal methods and systems for the delivery of anti-migraine compounds
Apr, 2027

(3 years from now)

US8155737 TEVA BRANDED PHARM Pharmacokinetics of iontophoretic sumatriptan administration
Apr, 2027

(3 years from now)

US9272137 TEVA BRANDED PHARM Transdermal methods and systems for the delivery of anti-migraine compounds
Sep, 2027

(3 years from now)

US8366600 TEVA BRANDED PHARM Polyamine enhanced formulations for triptan compound iontophoresis
Apr, 2029

(5 years from now)

US8983594 TEVA BRANDED PHARM Electronic control of drug delivery system
Nov, 2030

(6 years from now)

US9327114 TEVA BRANDED PHARM User-activated self-contained co-packaged iontophoretic drug delivery system
Oct, 2032

(8 years from now)

Market Authorisation Date: 17 January, 2013

Treatment: Method for treating acute migraine in adults, with or without aura, comprising iontophoretic transdermal delivery of sumatriptan or a salt thereof; Method for treating acute migraine in adults, with ...

Dosage: SYSTEM;IONTOPHORESIS

More Information on Dosage

ZECUITY family patents

Family Patents

5. Zembrace Symtouch patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11364224 UPSHER SMITH LABS Pharmaceutical composition for treating migraine
Jan, 2036

(11 years from now)

US10537554 UPSHER SMITH LABS Pharmaceutical composition for treating migraine
Jan, 2036

(11 years from now)

Market Authorisation Date: 28 January, 2016

Treatment: Treatment of migraine

Dosage: SOLUTION;SUBCUTANEOUS

More Information on Dosage

ZEMBRACE SYMTOUCH family patents

Family Patents